HF
BCRX icon

HRT Financial’s BioCryst Pharmaceuticals BCRX Stock Holding History

HRT Financial’s Portfolio BCRX Stock Details BCRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$10.8M Buy
+1,081,523
New +$9.78M 0.02% 741
2026
Q1 		– Sell
-716,826
Closed -$5.59M – 3797
2025
Q4 		$5.59M Buy
716,826
+658,920
+1,138% +$4.76M 0.02% 735
2025
Q3 		$439K Sell
57,906
-66,714
-54% -$556K ﹤0.01% 1957
2025
Q2 		$1.12M Buy
124,620
+66,551
+115% +$620K ﹤0.01% 1213
2025
Q1 		$435K Buy
+58,069
New +$468K ﹤0.01% 1540
2024
Q4 		– Sell
-20,044
Closed -$152K – 2442
2024
Q3 		$152K Buy
+20,044
New +$152K ﹤0.01% 2017
2024
Q1 		– Sell
-292,412
Closed -$1.75M – 2329
2023
Q4 		$1.75M Buy
292,412
+79,714
+37% +$462K 0.01% 714
2023
Q3 		$1.5M Buy
212,698
+68,636
+48% +$493K 0.02% 760
2023
Q2 		$1.01M Buy
144,062
+81,839
+132% +$657K 0.01% 944
2023
Q1 		$518K Buy
+62,223
New +$599K 0.01% 1353
2022
Q4 		– Sell
-23,803
Closed -$299K – 2467
2022
Q3 		$299K Buy
+23,803
New +$306K ﹤0.01% 2002
2021
Q4 		– Sell
-126,125
Closed -$1.81M – 3190
2021
Q3 		$1.81M Buy
126,125
+7,575
+6% +$119K 0.01% 809
2021
Q2 		$1.87M Buy
118,550
+78,720
+198% +$1.07M 0.02% 659
2021
Q1 		$405K Sell
39,830
-261,852
-87% -$2.7M ﹤0.01% 1939
2020
Q4 		$2.25M Buy
+301,682
New +$1.56M 0.05% 300
2019
Q4 		– Sell
-77,424
Closed -$221K – 1152
2019
Q3 		$221K Buy
+77,424
New +$241K 0.01% 1096
2015
Q3 		– Sell
-10,973
Closed -$163K – 90
2015
Q2 		$163K Buy
+10,973
New +$125K 0.08% 127

Other funds holding BCRX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return

HRT Financial's BCRX Position: Q2 2026 in Review

HRT Financial opened a new position in BioCryst Pharmaceuticals (BCRX) in Q2 2026: 1,081,523 shares worth $10.8M. The stake represents 0.02% of the portfolio and ranks #741 among its holdings. This is a return to the name: HRT Financial previously reported a position in BCRX as recently as Q4 2025.

HRT Financial first reported a position in BCRX in Q2 2015 and has held it in 17 quarters since. 318 funds tracked by Wall St. Rank hold BCRX as of Q2 2026.

  • HRT Financial held 1,081,523 shares of BioCryst Pharmaceuticals worth $10.8M as of Q2 2026.
  • BioCryst Pharmaceuticals was a new HRT Financial position in Q2 2026.
  • BioCryst Pharmaceuticals made up 0.02% of HRT Financial's portfolio in Q2 2026, its #741 holding.
  • HRT Financial first reported a position in BioCryst Pharmaceuticals in Q2 2015 and has held it in 17 quarters since.
  • 318 funds tracked by Wall St. Rank held BioCryst Pharmaceuticals as of Q2 2026.

Based on HRT Financial's 13F filing for Q2 2026, filed 14 Aug 2026.